Editas ‘pleased’ U.S. appeals court affirmed favorable USPTO decision

Editas Medicine announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. Patent and Trademark Office decision that ended the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad Institute, Inc. concerning certain CRISPR/Cas9 patents Editas Medicine exclusively licenses from Broad. This favorable action by the CAFC upholds the USPTO decision issued in February 2017, granting Broad’s motion for no interference-in-fact. “We are pleased with the Federal Circuit’s decision affirming the Patent Trial and Appeal Board decision on the patents that were granted to the Broad Institute for its innovative and fundamental work on CRISPR/Cas9 genome editing,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “This decision is highly favorable for Editas and for the Broad as it reaffirms the strength of our intellectual property foundation and has profound implications for making CRISPR medicines.”
https://thefly.com/landingPageNews.php?id=2788141